Tags

Type your tag names separated by a space and hit enter

Probiotic agents in the treatment of irritable bowel syndrome.

Abstract

Irritable bowel syndrome (IBS) is characterized by abdominal pain and alterations in bowel habits. Several pathogenetic factors, such as altered intestinal motility, visceral hypersensitivity, serotonin system abnormalities and psychic disturbances have been identified. Recently, a pathogenetic role of intestinal microflora has been shown in IBS: viral or bacterial infection can trigger post-infectious IBS; some patients have small intestinal bacterial overgrowth; the composition of patients' enteric flora is altered; and minimal inflammatory changes, consistent with the pro-inflammatory role of bacteria, have been demonstrated. Probiotics may, therefore, offer a rational therapeutic approach to IBS. The data available on the use of probiotics in IBS are still limited and results of controlled clinical trials are contradictory because they have been performed using different species, dosages, treatment durations and end-points for results evaluation. A critical evaluation of the therapeutic role of the various probiotics in IBS is presented in this article.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    Gastroenterology Unit, S. Raffaele University Hospital, Milan, Italy. guslandi.mario@hsr.it

    Source

    MeSH

    Clinical Trials as Topic
    Humans
    Intestines
    Irritable Bowel Syndrome
    Probiotics

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    17900396

    Citation

    Guslandi, M. "Probiotic Agents in the Treatment of Irritable Bowel Syndrome." The Journal of International Medical Research, vol. 35, no. 5, 2007, pp. 583-9.
    Guslandi M. Probiotic agents in the treatment of irritable bowel syndrome. J Int Med Res. 2007;35(5):583-9.
    Guslandi, M. (2007). Probiotic agents in the treatment of irritable bowel syndrome. The Journal of International Medical Research, 35(5), pp. 583-9.
    Guslandi M. Probiotic Agents in the Treatment of Irritable Bowel Syndrome. J Int Med Res. 2007;35(5):583-9. PubMed PMID: 17900396.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Probiotic agents in the treatment of irritable bowel syndrome. A1 - Guslandi,M, PY - 2007/9/29/pubmed PY - 2007/11/14/medline PY - 2007/9/29/entrez SP - 583 EP - 9 JF - The Journal of international medical research JO - J. Int. Med. Res. VL - 35 IS - 5 N2 - Irritable bowel syndrome (IBS) is characterized by abdominal pain and alterations in bowel habits. Several pathogenetic factors, such as altered intestinal motility, visceral hypersensitivity, serotonin system abnormalities and psychic disturbances have been identified. Recently, a pathogenetic role of intestinal microflora has been shown in IBS: viral or bacterial infection can trigger post-infectious IBS; some patients have small intestinal bacterial overgrowth; the composition of patients' enteric flora is altered; and minimal inflammatory changes, consistent with the pro-inflammatory role of bacteria, have been demonstrated. Probiotics may, therefore, offer a rational therapeutic approach to IBS. The data available on the use of probiotics in IBS are still limited and results of controlled clinical trials are contradictory because they have been performed using different species, dosages, treatment durations and end-points for results evaluation. A critical evaluation of the therapeutic role of the various probiotics in IBS is presented in this article. SN - 0300-0605 UR - https://www.unboundmedicine.com/medline/citation/17900396/Probiotic_agents_in_the_treatment_of_irritable_bowel_syndrome_ L2 - http://journals.sagepub.com/doi/full/10.1177/147323000703500501?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -